Corcept Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 10,357 3,307 - -
Cost of Revenue 143 91 - -
Gross Profit 10,214 3,216 - -
Operating Expenses
Research and Development 20,470 14,074 21,001 18,949
Sales, General and Admin. 31,240 25,414 11,331 8,488
Non-Recurring Items - - - -
Other - - - -
Operating Income (41,496) (36,272) (32,332) (27,437)
Income From Continuing Operations
Add'l Income/Expense Items - - 3 1,496
Earnings Before Interest and Tax (41,496) (36,272) (32,329) (25,941)
Interest Expense 4,515 1,776 25 25
Earnings Before Tax (46,011) (38,048) (32,354) (25,966)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (46,011) (38,048) (32,354) (25,966)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (46,011) (38,048) (32,354) (25,966)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (46,011) (38,048) (32,354) (25,966)